.
"we can only imagine the terror that she experienced on her own, dying on the floor in pain.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. 'cut short' by james taylor is published on june 1 by white owl books, price ?20.
.